Hi Mrdog,
To answer your first question, second and third line patients are those who have colorectal cancer which has progressed after treatment (the first or second line chemotherapy)
Secondly irinotecan-naïve does indeed mean patients who have not previously been treated with irinotecan. This is important, as patients who have, and have progressed, are likely to have cancers which have potentially mutated to resist treatment with irinotecan.
To answer the third question, I don't know about the distribution of patients, but the randomisation method would consider patient treatment site, and it is unlikely that there will be any statistically significant difference in survivals between control and treatment groups due based solely on differing geography. There are certainly Australian patients, as about six months ago I had to field a question regarding one (nothing remotely interesting or market sensitive).
All else said and done, I'm feeling quite positive regarding the trial at this point.
- Forums
- ASX - By Stock
- TSN
- questions re phase 3 trial
questions re phase 3 trial, page-2
-
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
AHK
ARK MINES LIMITED
Ben Emery, Executive Director
Ben Emery
Executive Director
SPONSORED BY The Market Online